103 results match your criteria: "University College London Hospitals Trust.[Affiliation]"
Ageing Res Rev
December 2024
Division of Psychiatry, University College London, Maple House, 149 Tottenham Court Road, London W1T 7NF, UK; North London NHS Foundation Trust, London, 4 St Pancras Way, London NW1 0PE, UK. Electronic address:
Background And Objective: People with adult-onset hearing loss (AoHL) are at increased dementia risk. In this study, we explore potential aetiological mechanisms by synthesising the evidence on the association between AoHL and neuropathological, cerebrospinal fluid (CSF), blood and imaging biomarkers of dementia.
Methods: We systematically searched electronic databases from inception to 30 April 2024 for cross-sectional and longitudinal studies, including quantitative data on the association between AoHL and dementia biomarkers.
Eur Urol
September 2024
Division of Surgery and Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospitals Trust, London, UK.
Background And Objective: The PRECISION and PRECISE trials compared magnetic resonance imaging targeted biopsy (MRI ± TB) with the standard transrectal ultrasound (TRUS) guided biopsy for the detection of clinically significant prostate cancer (csPCa). PRECISION demonstrated superiority of MRI ± TB over TRUS guided biopsy, while PRECISE demonstrated noninferiority. The VISION study is a planned individual patient data meta-analysis (IPDMA) comparing MRI ± TB with TRUS guided biopsy for csPCa diagnosis.
View Article and Find Full Text PDFEur Urol Oncol
July 2024
St Vincent's Prostate Cancer Research Centre, Department of Urology, Sydney, Australia.
Eur Urol Open Sci
June 2024
Division of Surgical & Interventional Science, University College London, London, UK.
Background And Objective: Radical prostatectomy (RP) is an established treatment for localised prostate cancer that can have a significant impact on urinary and sexual function, with recovery over time. Our aim was to describe functional recovery in the first year after RP, reporting descriptive outcomes alongside validated patient-reported outcome measure scores (Expanded Prostate Cancer Index Composite, EPIC-26).
Methods: Men undergoing RP between September 2015 and November 2019 completed EPIC-26 at baseline and 1, 3, 6, and 12 mo.
Nat Commun
March 2024
1st Department of Otolaryngology, Hippocration Hospital Athens, National & Kapodistrian University of Athens, Athens, Greece.
Inhibition of Notch signalling with a gamma-secretase inhibitor (GSI) induces mammalian hair cell regeneration and partial hearing restoration. In this proof-of-concept Phase I/IIa multiple-ascending dose open-label trial (ISRCTN59733689), adults with mild-moderate sensorineural hearing loss received 3 intratympanic injections of GSI LY3056480, in 1 ear over 2 weeks. Phase I primary outcome was safety and tolerability.
View Article and Find Full Text PDFEur Urol
February 2024
UConn Health, Farmington, CT, USA.
BMJ
October 2023
Chelsea & Westminster NHS Foundation Trust, London SW10 9NH, UK.
Oral Dis
May 2024
Department of Maxillofacial Medicine and Surgery, UCL Eastman Dental Institute, University College London, London, UK.
Objectives: The aim of this cross-sectional study was to explore the structural validity and internal consistency reliability of General Anxiety Disorder-7, Patient Health Questionnaire-8, 15 and Jaw Functional Limitation Scale-20 in patients with chronic pain of temporomandibular disorders.
Materials And Methods: Validity and reliability were assessed in 129 patients diagnosed according to the diagnostic criteria for temporomandibular disorders. Structural validity was explored using factor analysis, and internal consistency by calculating Cronbach α.
J Int Adv Otol
October 2023
National Institute for Health Research, University College London Hospitals Biomedical Research Centre, UK; evidENT, Ear Institute, University College London, UK; Royal National ENT and Eastman Dental Hospitals, University College London Hospitals Trust, UK.
Recent breakthroughs in our understanding of sensorineural hearing loss etiology have encouraged the identification of novel hearing therapeutics, paving the way for precision hearing medicine. Critical to this field is the curation of health resources on hearing data. A systematic review of the literature was conducted to map existing (inter)national and regional datasets that include hearing data to inform the development of future hearing repositories.
View Article and Find Full Text PDFProstate
January 2024
Division of Urological Surgery and Center of Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Background: Real-world data on racial differences in the side effects of radical prostatectomy on quality of life (QoL) are lacking. We aimed to evaluate differences in patient-reported outcome measure (PROM) among non-Hispanic Black (NHB) and non-Hispanic White (NHW) men using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) questionnaire to measure health-related QoL after radical prostatectomy.
Methods: We retrospectively assessed prospectively collected PROMs using EPIC-CP scores at a tertiary care center between 2015 and 2021 for men with prostate cancer undergoing radical prostatectomy.
J Oral Pathol Med
October 2023
Department of Maxillofacial Medicine and Surgery, UCL Eastman Dental Institute, University College London, London, UK.
Introduction: The importance of the patients' clinical experience has been reinforced several times over the last decade by healthcare organisations and policy makers. Routine gathering of experience data can help in enhancing patient-centred care and provide guidance to quality improvement schemes. Patient-reported experience measures can help to that end.
View Article and Find Full Text PDFWorld J Urol
May 2023
Division of Urological Surgery and Center of Surgery and Public Health, Brigham and Women's Hospital, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Purpose: To describe the national-level patterns of care for local ablative therapy among men with PCa and identify patient- and hospital-level factors associated with the receipt of these techniques.
Methods: We retrospectively interrogated the National Cancer Database (NCDB) for men with clinically localized PCa between 2010 and 2017. The main outcome was receipt of local tumor ablation with either cryo- or laser-ablation, and "other method of local tumor destruction including high-intensity focused ultrasound (HIFU)".
BJU Int
April 2023
British Urology Researchers in Surgical Training (BURST) Collaborative, London, UK.
Eur Urol Oncol
April 2023
Academic Urology Unit, Aberdeen University, Aberdeen, UK.
Background: Active surveillance (AS) is recommended for low-risk and some intermediate-risk prostate cancer. Uptake and practice of AS vary significantly across different settings, as does the experience of surveillance-from which tests are offered, and to the levels of psychological support.
Objective: To explore the current best practice and determine the most important research priorities in AS for prostate cancer.
Oral Dis
October 2023
Department of Maxillofacial Medicine and Surgery, UCL Eastman Dental Institute, University College London, London, UK.
Objectives: To explore the experiences of patients with temporomandibular disorders (TMDs) with the National Health Service and to discover their healthcare priorities when seeking treatment.
Methods: Semi-structured interviews were used. They were directed using a topic guide covering subjects such as initial visits in primary care, referrals to secondary care, and the effect on symptoms.
Nat Rev Urol
February 2023
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Androgen deprivation therapy (ADT) alone has been the cornerstone of treatment for patients with newly diagnosed metastatic prostate cancer for the past century. Based on results from landmark trials in the past decade, combination approaches of ADT with chemotherapy or novel hormonal agents have established a new standard of care for these patients. This paradigm shift in treatment has been reflected in the updates to guideline recommendations of major professional associations.
View Article and Find Full Text PDFEur Urol Open Sci
July 2022
Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Background: Active surveillance (AS) is a management option for men diagnosed with low-risk prostate cancer. Opinions differ on whether it is safe to include young men (≤60 yr) or men with intermediate-risk disease.
Objective: To assess whether reasons for discontinuation, treatment choice after AS, and adverse pathology at radical prostatectomy (RP; N1, or ≥GG3, or ≥pT3) differ for men ≤60 yr or those with European Association of Urology (EAU) intermediate-risk disease from those for men >60 yr or those with EAU low-risk disease.
Br Dent J
July 2022
Consultant Oral Surgeon, Oral Surgery Unit, Royal National ENT and Eastman Dental Hospitals, University College London Hospitals Trust, London, UK.
Medicine and dentistry have historically existed as separate entities, resulting in the creation of separate patient health records, which may limit patient care and safety. The General Dental Council emphasise the need to 'make and keep contemporaneous, complete and accurate patient records' as part of the expected standards of the dental team, with no suggested preference on paper or electronic notes. Despite offering clear advantages in primary care dental practice for efficiency, patient accessibility and financial benefit, the comparatively limited uptake of electronic records in dentistry in the secondary care setting has created barriers for patients and clinicians in delivery of evidence-based oral care.
View Article and Find Full Text PDFBJU Int
November 2022
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
PLoS One
March 2022
Division of Surgery and Interventional Sciences, University College London, United Kingdom.
Background: Transrectal ultrasound (TRUS) guided biopsy for prostate cancer is prone to random and systemic error and has been shown to have a negative predictive value of 70%. PRECISION and PRECISE are among the first randomised studies to evaluate the new MRI-targeted biopsy (MRI-TB) pathway with a non-paired design to detect clinically significant prostate cancer and avoid unnecessary treatment. The trials' results individually demonstrated non-inferiority of MRI-TB compared to TRUS biopsy.
View Article and Find Full Text PDFEur Urol
April 2022
Division of Surgical and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals Trust, London, UK. Electronic address:
Eur Urol Open Sci
January 2022
Lille University Medical Center, Lille, France.
Background: The inclusion criterion for active surveillance (AS) is low- or intermediate-risk prostate cancer. The predictive value of the presence of a suspicious lesion at magnetic resonance imaging (MRI) at the time of inclusion is insufficiently known.
Objective: To evaluate the percentage of patients needing active treatment stratified by the presence or absence of a suspicious lesion at baseline MRI.
J Clin Oncol
September 2021
School of Dental Medicine & Neag Comprehensive Cancer Center, UConn Health, Farmington, CT.
AJR Am J Roentgenol
December 2021
Department of Urology and Division of Surgical and Interventional Science, University College London Hospitals Trust, London, UK.
Prostate cancer is the second most common malignancy in men worldwide. Systematic transrectal prostate biopsy is commonly used to obtain tissue to establish the diagnosis. In recent years, however, more clinically significant cancer and less clinically insignificant cancer have been detected with MRI targeted biopsy (on the basis of an MRI examination performed before consideration of biopsy) than with systematic biopsy.
View Article and Find Full Text PDFBiomed Opt Express
February 2021
Department of Medical Physics & Biomedical Engineering, University College London, London, WC1E 6BT, UK.
Tissue oximetry with near-infrared spectroscopy (NIRS) is a technique for the measurement of absolute tissue oxygen saturation (StO). Offering a real-time and non-invasive assessment of brain oxygenation and haemodynamics, StO has potential to be used for the assessment of newborn brain injury. Multiple algorithms have been developed to measure StO, however, issues with low measurement accuracy or extracranial tissue signal contamination remain.
View Article and Find Full Text PDF